Published in Onkologie on January 22, 2010
Case Numbers and Process Quality in Breast Surgery in Germany: A Retrospective Analysis of Over 150,000 Patients From 2013 to 2014. Dtsch Arztebl Int (2015) 0.84
Provision of breast cancer care and survival in Germany - results from a population-based high resolution study from Saarland. BMC Cancer (2014) 0.75
The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients. BMC Cancer (2015) 0.75
[Compliance of patients concerning recommended radiotherapy in breast cancer : Association with recurrence, age, and hormonal therapy]. Strahlenther Onkol (2012) 0.75
Supporting breast cancer decisions using formalized guidelines and experts decision patterns: initial prototype and evaluation. Health Inf Sci Syst (2017) 0.75
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst (2013) 3.46
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 2.47
Work-life balance of German gynecologists: a web-based survey on satisfaction with work and private life. Arch Gynecol Obstet (2013) 2.27
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol (2010) 1.71
Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology (2010) 1.70
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol (2009) 1.68
Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer (2007) 1.62
Uterine arteriovenous malformations induced after diagnostic curettage: a systematic review. Arch Gynecol Obstet (2011) 1.42
Ovarian metastasis of a lymphoma presenting as primary ovarian cancer. Onkologie (2009) 1.40
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol (2013) 1.36
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol (2009) 1.31
Interleukin 21-induced granzyme B-expressing B cells infiltrate tumors and regulate T cells. Cancer Res (2013) 1.27
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res (2012) 1.22
Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett (2006) 1.21
Angiogenesis in the corpus luteum. Reprod Biol Endocrinol (2003) 1.20
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
Exacerbation of a maternal hiatus hernia in early pregnancy presenting with symptoms of hyperemesis gravidarum: case report and review of the literature. Arch Gynecol Obstet (2010) 1.18
Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro. Angiogenesis (2005) 1.16
Effects of guideline adherence in primary breast cancer--a 5-year multi-center cohort study of 3976 patients. Breast (2010) 1.15
Survival of patients with bilateral versus unilateral breast cancer and impact of guideline adherent adjuvant treatment: a multi-centre cohort study of 5292 patients. Breast (2011) 1.14
Bevacizumab in the treatment of ovarian cancer. Adv Ther (2012) 1.12
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol (2010) 1.11
Prospective evaluation of factors influencing success rates of sentinel node biopsy in 814 breast cancer patients. Cancer Biother Radiopharm (2004) 1.10
Chlamydia trachomatis infection as a risk factor for infertility among women in Ghana, West Africa. Am J Trop Med Hyg (2008) 1.10
Risk awareness and transparency. Dtsch Arztebl Int (2013) 1.10
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer (2011) 1.09
Retziusscopy: a minimal invasive technique for the treatment of retropubic hematomas after TVT procedure. Eur J Obstet Gynecol Reprod Biol (2011) 1.05
Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics (2002) 1.03
[Short version of the guideline "Early Detection of Breast Cancer in Germany"]. Z Arztl Fortbild Qualitatssich (2004) 1.03
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther (2002) 1.03
Hemorrhagic complications associated with tension-free vaginal tape procedure. Obstet Gynecol (2004) 1.01
VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol (2012) 0.99
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol (2003) 0.99
Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res (2004) 0.99
Role of SIRT1 in homologous recombination. DNA Repair (Amst) (2010) 0.99
Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology (2002) 0.98
Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol (2005) 0.98
On the difference of micronucleus frequencies in peripheral blood lymphocytes between breast cancer patients and controls. Mutagenesis (2006) 0.98
Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response. Oncol Rep (2004) 0.97
Tspan-1 is a tetraspanin preferentially expressed by mucinous and endometrioid subtypes of human ovarian carcinomas. Cancer Lett (2008) 0.96
Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer (2012) 0.96
Angiogenesis during primate placentation in health and disease. Reproduction (2003) 0.95
Progression of cervical carcinomas is associated with down-regulation of CD9 but strong local re-expression at sites of transendothelial invasion. Clin Cancer Res (2003) 0.95
Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Res Treat (2013) 0.93
Prediction of nodal involvement in breast cancer based on multiparametric protein analyses from preoperative core needle biopsies of the primary lesion. Clin Cancer Res (2008) 0.93
First Revision of the German S3 Guideline 'Diagnosis, Therapy, and Follow-Up of Breast Cancer' Breast Care (Basel) (2008) 0.93
Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol (2002) 0.93
Certification of breast centres in Germany: proof of concept for a prototypical example of quality assurance in multidisciplinary cancer care. BMC Cancer (2009) 0.93
Local Renin-Angiotensin system in the reproductive system. Front Endocrinol (Lausanne) (2013) 0.93
CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans. Int J Mol Med (2007) 0.92
Accelerated partial breast irradiation: consensus statement of 3 German Oncology societies. Cancer (2007) 0.92
Zurich Consensus: German Expert Opinion on the St. Gallen Votes on 15 March 2009 (11th International Conference at St. Gallen: Primary Therapy of Early Breast Cancer). Breast Care (Basel) (2009) 0.92
Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood (2002) 0.92
Heritability of baseline and induced micronucleus frequencies. Mutagenesis (2011) 0.92
Mastectomy trends for early-stage breast cancer: a report from the EUSOMA multi-institutional European database. Eur J Cancer (2012) 0.92
Optimizing the quality of breast cancer care at certified german breast centers: a benchmarking analysis for 2003-2009 with a particular focus on the interdisciplinary specialty of radiation oncology. Strahlenther Onkol (2011) 0.91
Haemorrhage and nerve damage as complications of TVT-O procedure: case report and literature review. Arch Gynecol Obstet (2007) 0.90
Long-term results of the tension-free vaginal tape procedure in an unselected group: a 7-year follow-up study. Urology (2011) 0.90
German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol (2013) 0.89
Cryobanking of human ovarian tissue for anti-cancer treatment: comparison of vitrification and conventional freezing. Cryo Letters (2010) 0.89
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol (2013) 0.89
Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix. Int J Gynecol Cancer (2014) 0.88
Adherence to treatment guidelines and survival in triple-negative breast cancer: a retrospective multi-center cohort study with 9,156 patients. BMC Cancer (2013) 0.88
Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. Oncol Rep (2003) 0.87
Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. Cancer Lett (2002) 0.87
The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility. FASEB J (2012) 0.86
2008 update of the guideline: early detection of breast cancer in Germany. J Cancer Res Clin Oncol (2008) 0.86
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. Onkologie (2010) 0.86
A novel breast cancer cell line initially established from pleural effusion: evolution towards a more aggressive phenotype. Int J Oncol (2007) 0.86
Re-vascularisation in human ovarian tissue after conventional freezing or vitrification and xenotransplantation. Eur J Obstet Gynecol Reprod Biol (2009) 0.86
Patients undergoing frozen-thawed embryo transfer have similar live birth rates in spontaneous and artificial cycles. J Assist Reprod Genet (2012) 0.86
Pretreatment staging of cervical cancer: is imaging better than palpation?: Role of CT and MRI in preoperative staging of cervical cancer: single institution results for 255 patients. Ann Surg Oncol (2008) 0.86
Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol (2003) 0.85
Partial breast irradiation after breast-conserving surgery. Strahlenther Onkol (2005) 0.85
High level of transgene expression in primary chronic lymphocytic leukemia cells using helper-virus-free recombinant Epstein-Barr virus vectors. Exp Hematol (2003) 0.85
[Effects of guideline-compliant therapy on the survival of primary breast cancer patients with: results of a retrospective cohort study]. Z Evid Fortbild Qual Gesundhwes (2011) 0.85